DOCSLIB.ORG

Observational Study Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Observational Study Protocol Company substance code: 280922 EMR700568-012 Cladribine Observational Study Protocol Study Protocol Number EMR700568-012 Title Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). EudraCT Number 2009-017978-21 Sponsor In USA EMD Serono, Inc. An affiliate of Merck KGaA, Darmstadt, Germany One Technology Place, Rockland, MA02370 Phone: +1 781 982 9000 Fax: +1 781 681 2902 In Rest of The World Merck Serono SA – Geneva An affiliate of Merck KGaA, Darmstadt, Germany 29 quai des Bergues 1201 Geneva / Switzerland Medical Responsible PPD EMD Serono Research & Development Institute, Inc. A subsidiary of Merck KGaA, Darmstadt, Germany 45A Middlesex Turnpike Billerica MA 01821, USA Phone: PPD E-mail: PPD Sponsor’s Legal Representative Merck KGaA, Frankfurter Strasse 250, 64293 (EU) Darmstadt, Germany Study Protocol Version 20 July 2016 /Version 4.0 including amendment No. 2 'RFXPHQW1RCCI 1/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine Replaces Study Protocol Version Version 3.0; 23 July 2012 Current Protocol Amendment Amendment No. 2 (Global), 20 July 2016 This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. It is intended for restricted use only and may not – in full or part – be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany, or its affiliate. Copyright © 2016 by Merck KGaA, Darmstadt, Germany, or its subsidiary. All rights reserved 'RFXPHQW1RCCI 2/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine SIGNATURE PAGE Protocol Lead responsible for designing the study: I approve the design of the study. Signature Date of Signature PPD EMD Serono Research & Development Institute, Inc. A subsidiary of Merck KGaA, Darmstadt, Germany 45A Middlesex Turnpike Billerica MA 01821, USA Phone: PPD E-mail: PPD 'RFXPHQW1RCCI 3/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine PRINCIPAL REGISTRY PHYSICIAN SIGNATURE Study Title: Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Protocol Version/Date: Version 4.0 including amendment 2 / 20 July 2016 Center Number: Principal Registry Physician’s site number in the registry Principal Registry Physician: Principal Registry Physician’s full name, title and academic degree (e.g., Associate Professor, M.D., M.Sc., Prof. Dr. med., etc.) I, the undersigned, am responsible for the conduct of the registry at this site and affirm that ! I understand and will conduct the registry according to the protocol, any approved protocol amendments, Good Pharmacoepidemiology Practices (GPP) [1], Good Clinical Practice [2] and all applicable Regulatory Authority requirements and national laws. ! I will not deviate from the protocol without prior written permission from the Sponsor and prior review and written approval from the Institutional Review Board or Independent Ethics Committee, except where necessary to prevent immediate danger to a subject. Signature Date of Signature Insert Name, academic qualifications Insert Position (job title) Insert Address of Institution Insert Phone, fax, e-mail Each Principal Registry Physician (PRP) will sign a copy of this page. The original signed signature sheets will be filed in the Registry Master File. 'RFXPHQW1RCCI 4/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine Further Sponsor Responsible Persons PPD EMD Serono Research & Development Institute, Inc. A subsidiary of Merck KGaA, Darmstadt, Germany 45A Middlesex Turnpike Billerica, MA 01821, USA Phone: PPD Email: PPD PPD EMD Serono Research & Development Institute, Inc. A subsidiary of Merck KGaA, Darmstadt, Germany One Technology Place Rockland, MA02370, USA Phone: PPD E-mail address: PPD 'RFXPHQW1RCCI 5/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine Table of contents Table of contents ..............................................................................................................6 Table of Figures ..............................................................................................................8 List of Abbreviations ...........................................................................................................9 1 Synopsis..............................................................................................11 2 Sponsor, registry physicians and Study Administrative Structure .....14 3 Background Information.....................................................................15 4 Study Objectives.................................................................................17 5 Study design........................................................................................18 5.1 Study Population.................................................................................18 5.2 Study Enrollment................................................................................18 5.2.1 Physician Enrollment..........................................................................18 5.2.2 Subject Enrollment .............................................................................19 5.3 Inclusion Criteria ................................................................................19 5.4 Exclusion Criteria ...............................................................................19 5.5 Study Region/Location .......................................................................20 5.6 Study Cohort.......................................................................................20 5.7 Follow-up and Study Duration ...........................................................20 5.7.1 Study Termination ..............................................................................21 5.7.2 Lost to Follow-up ...............................................................................21 6 Study Endpoints..................................................................................21 6.1 Primary Endpoints ..............................................................................21 6.2 Secondary Endpoint............................................................................22 6.3 Definitions related to study Endpoints ...............................................22 7 Assessment of Medication Exposure..................................................24 7.1 Prior Exposure to Cladribine ..............................................................24 8 Data sources and Study Procedures....................................................24 8.1 Data Sources .......................................................................................25 8.2 Schedule of Interviews and Subject Questionnaires...........................26 8.3 Baseline Subject Demographic and Other Characteristics .................26 8.3.1 Registry Baseline Data Elements........................................................27 8.3.1.1 Information from registry enrollment interview.................................27 'RFXPHQW1RCCI 6/51 2EMHFW1RCCI Company substance code: 280922 EMR700568-012 Cladribine 8.3.1.2 Information from medical health records review ...............................27 8.3.1.3 Data elements from the clinical trial database....................................27 8.3.1.4 Interviews at pregnancy baseline and offspring baseline ...................28 8.4 Follow-Up Interviews.........................................................................29 8.5 Reporting of Adverse events ..............................................................30 8.5.1 Definitions ..........................................................................................31 8.5.1.1 Adverse Events ...................................................................................31 8.5.1.2 Adverse Drug Reaction.......................................................................31 8.5.1.3 Serious Adverse Events ......................................................................31 8.5.1.4 Serious Adverse Drug Reaction..........................................................32 8.5.1.5 Definition of the Adverse Event Reporting Period.............................33 8.5.2 Recording of Adverse Events in the CRF (Methods of Recording and Assessing Adverse Events)..........................................................33 8.5.3 Procedure for Reporting Serious Adverse Events ..............................34 8.5.3.1 Pregnancy and In Utero Drug Exposure.............................................34 8.5.4 Safety Reporting to Regulatory Authorities, Investigators and Independent Ethics Committees/Institutional Review Boards ...........35 9 Data Analysis and Statistics................................................................36 9.1 Registry size........................................................................................36 9.2 Data analysis.......................................................................................36 9.2.1 General Considerations.......................................................................36 9.2.2 Treatment/Analysis Period .................................................................37 9.3 Study Reporting and Analysis ............................................................37 9.3.1 Missing Data.......................................................................................38 10 Ethical, Scientific and Regulatory Aspects ........................................38
Load more

Recommended publications
  • Observational Clinical Research
    E REVIEW ARTICLE Clinical Research Methodology 2: Observational Clinical Research Daniel I. Sessler, MD, and Peter B. Imrey, PhD * † Case-control and cohort studies are invaluable research tools and provide the strongest fea- sible research designs for addressing some questions. Case-control studies usually involve retrospective data collection. Cohort studies can involve retrospective, ambidirectional, or prospective data collection. Observational studies are subject to errors attributable to selec- tion bias, confounding, measurement bias, and reverse causation—in addition to errors of chance. Confounding can be statistically controlled to the extent that potential factors are known and accurately measured, but, in practice, bias and unknown confounders usually remain additional potential sources of error, often of unknown magnitude and clinical impact. Causality—the most clinically useful relation between exposure and outcome—can rarely be defnitively determined from observational studies because intentional, controlled manipu- lations of exposures are not involved. In this article, we review several types of observa- tional clinical research: case series, comparative case-control and cohort studies, and hybrid designs in which case-control analyses are performed on selected members of cohorts. We also discuss the analytic issues that arise when groups to be compared in an observational study, such as patients receiving different therapies, are not comparable in other respects. (Anesth Analg 2015;121:1043–51) bservational clinical studies are attractive because Group, and the American Society of Anesthesiologists they are relatively inexpensive and, perhaps more Anesthesia Quality Institute. importantly, can be performed quickly if the required Recent retrospective perioperative studies include data O 1,2 data are already available.
    [Show full text]
  • NIH Definition of a Clinical Trial
    UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM NIH Definition of a Clinical Trial The NIH has recently changed their definition of clinical trial. This Fact Sheet provides information regarding this change and what it means to investigators. NIH guidelines include the following: “Correctly identifying whether a study is considered to by NIH to be a clinical trial is crucial to how [the investigator] will: Select the right NIH funding opportunity announcement for [the investigator’s] research…Write the research strategy and human subjects section of the [investigator’s] grant application and contact proposal…Comply with appropriate policies and regulations, including registration and reporting in ClinicalTrials.gov.” NIH defines a clinical trial as “A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.” NIH notes, “The term “prospectively assigned” refers to a pre-defined process (e.g., randomization) specified in an approved protocol that stipulates the assignment of research subjects (individually or in clusters) to one or more arms (e.g., intervention, placebo, or other control) of a clinical trial. And, “An ‘intervention’ is defined as a manipulation of the subject or subject’s environment for the purpose of modifying one or more health-related biomedical or behavioral processes and/or endpoints. Examples include:
    [Show full text]
  • E 8 General Considerations for Clinical Trials
    European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION TO CPMP November 1996 TRANSMISSION TO INTERESTED PARTIES November 1996 DEADLINE FOR COMMENTS May 1997 FINAL APPROVAL BY CPMP September 1997 DATE FOR COMING INTO OPERATION March 1998 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: [email protected] http://www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GENERAL CONSIDERATIONS FOR CLINICAL TRIALS ICH Harmonised Tripartite Guideline Table of Contents 1. OBJECTIVES OF THIS DOCUMENT.............................................................................3 2. GENERAL PRINCIPLES...................................................................................................3 2.1 Protection of clinical trial subjects.............................................................................3 2.2 Scientific approach in design and analysis.................................................................3 3. DEVELOPMENT METHODOLOGY...............................................................................6 3.1 Considerations for the Development Plan..................................................................6 3.1.1 Non-Clinical Studies ........................................................................................6
    [Show full text]
  • Double Blind Trials Workshop
    Double Blind Trials Workshop Introduction These activities demonstrate how double blind trials are run, explaining what a placebo is and how the placebo effect works, how bias is removed as far as possible and how participants and trial medicines are randomised. Curriculum Links KS3: Science SQA Access, Intermediate and KS4: Biology Higher: Biology Keywords Double-blind trials randomisation observer bias clinical trials placebo effect designing a fair trial placebo Contents Activities Materials Activity 1 Placebo Effect Activity Activity 2 Observer Bias Activity 3 Double Blind Trial Role Cards for the Double Blind Trial Activity Testing Layout Background Information Medicines undergo a number of trials before they are declared fit for use (see classroom activity on Clinical Research for details). In the trial in the second activity, pupils compare two potential new sunscreens. This type of trial is done with healthy volunteers to see if the there are any side effects and to provide data to suggest the dosage needed. If there were no current best treatment then this sort of trial would also be done with patients to test for the effectiveness of the new medicine. How do scientists make sure that medicines are tested fairly? One thing they need to do is to find out if their tests are free of bias. Are the medicines really working, or do they just appear to be working? One difficulty in designing fair tests for medicines is the placebo effect. When patients are prescribed a treatment, especially by a doctor or expert they trust, the patient’s own belief in the treatment can cause the patient to produce a response.
    [Show full text]
  • Observational Studies and Bias in Epidemiology
    The Young Epidemiology Scholars Program (YES) is supported by The Robert Wood Johnson Foundation and administered by the College Board. Observational Studies and Bias in Epidemiology Manuel Bayona Department of Epidemiology School of Public Health University of North Texas Fort Worth, Texas and Chris Olsen Mathematics Department George Washington High School Cedar Rapids, Iowa Observational Studies and Bias in Epidemiology Contents Lesson Plan . 3 The Logic of Inference in Science . 8 The Logic of Observational Studies and the Problem of Bias . 15 Characteristics of the Relative Risk When Random Sampling . and Not . 19 Types of Bias . 20 Selection Bias . 21 Information Bias . 23 Conclusion . 24 Take-Home, Open-Book Quiz (Student Version) . 25 Take-Home, Open-Book Quiz (Teacher’s Answer Key) . 27 In-Class Exercise (Student Version) . 30 In-Class Exercise (Teacher’s Answer Key) . 32 Bias in Epidemiologic Research (Examination) (Student Version) . 33 Bias in Epidemiologic Research (Examination with Answers) (Teacher’s Answer Key) . 35 Copyright © 2004 by College Entrance Examination Board. All rights reserved. College Board, SAT and the acorn logo are registered trademarks of the College Entrance Examination Board. Other products and services may be trademarks of their respective owners. Visit College Board on the Web: www.collegeboard.com. Copyright © 2004. All rights reserved. 2 Observational Studies and Bias in Epidemiology Lesson Plan TITLE: Observational Studies and Bias in Epidemiology SUBJECT AREA: Biology, mathematics, statistics, environmental and health sciences GOAL: To identify and appreciate the effects of bias in epidemiologic research OBJECTIVES: 1. Introduce students to the principles and methods for interpreting the results of epidemio- logic research and bias 2.
    [Show full text]
  • Study Types Transcript
    Study Types in Epidemiology Transcript Study Types in Epidemiology Welcome to “Study Types in Epidemiology.” My name is John Kobayashi. I’m on the Clinical Faculty at the Northwest Center for Public Health Practice, at the School of Public Health and Community Medicine, University of Washington in Seattle. From 1982 to 2001, I was the state epidemiologist for Communicable Diseases at the Washington State Department of Health. Since 2001, I’ve also been the foreign adviser for the Field Epidemiology Training Program of Japan. About this Module The modules in the epidemiology series from the Northwest Center for Public Health Practice are intended for people working in the field of public health who are not epidemiologists, but who would like to increase their understanding of the epidemiologic approach to health and disease. This module focuses on descriptive and analytic epide- miology and their respective study designs. Before you go on with this module, we recommend that you become familiar with the following modules, which you can find on the Center’s Web site: What is Epidemiology in Public Health? and Data Interpretation for Public Health Professionals. We introduce a number of new terms in this module. If you want to review their definitions, the glossary in the attachments link at the top of the screen may be useful. Objectives By now, you should be familiar with the overall approach of epidemiology, the use of various kinds of rates to measure disease frequency, and the various ways in which epidemiologic data can be presented. This module offers an overview of descriptive and analytic epidemiology and the types of studies used to review and investigate disease occurrence and causes.
    [Show full text]
  • Developing a Protocol
    FACILITATOR/MENTOR GUIDE Developing a Protocol Created: 2013 Developing a Protocol. Atlanta, GA: Centers for Disease Control and Prevention (CDC), 2013. DEVELOPING A PROTOCOL Table of Contents LEARNING OBJECTIVES ................................................................................................... 3 ESTIMATED COMPLETION TIME ........................................................................................ 3 TARGET AUDIENCE ......................................................................................................... 3 PRE-WORK AND PREREQUISITES ..................................................................................... 3 MATERIALS .................................................................................................................... 4 OPTIONS FOR FACILITATING THIS TRAINING ....................................................................... 4 ICON GLOSSARY ............................................................................................................ 5 ACKNOWLEDGEMENTS .................................................................................................... 5 FACILITATOR RESPONSIBILITIES ...................................................................................... 7 SECTIONS 1 & 2: INTRODUCTION AND OVERVIEW .............................................................. 8 SECTION 3: WRITING A PROPOSAL OR CONCEPT PAPER ..................................................... 9 SECTION 4: WRITING A DRAFT OF THE PROTOCOL ...........................................................
    [Show full text]
  • Chapter 5 Experiments, Good And
    Chapter 5 Experiments, Good and Bad Point of both observational studies and designed experiments is to identify variable or set of variables, called explanatory variables, which are thought to predict outcome or response variable. Confounding between explanatory variables occurs when two or more explanatory variables are not separated and so it is not clear how much each explanatory variable contributes in prediction of response variable. Lurking variable is explanatory variable not considered in study but confounded with one or more explanatory variables in study. Confounding with lurking variables effectively reduced in randomized comparative experiments where subjects are assigned to treatments at random. Confounding with a (only one at a time) lurking variable reduced in observational studies by controlling for it by comparing matched groups. Consequently, experiments much more effec- tive than observed studies at detecting which explanatory variables cause differences in response. In both cases, statistically significant observed differences in average responses implies differences are \real", did not occur by chance alone. Exercise 5.1 (Experiments, Good and Bad) 1. Randomized comparative experiment: effect of temperature on mice rate of oxy- gen consumption. For example, mice rate of oxygen consumption 10.3 mL/sec when subjected to 10o F. temperature (Fo) 0 10 20 30 ROC (mL/sec) 9.7 10.3 11.2 14.0 (a) Explanatory variable considered in study is (choose one) i. temperature ii. rate of oxygen consumption iii. mice iv. mouse weight 25 26 Chapter 5. Experiments, Good and Bad (ATTENDANCE 3) (b) Response is (choose one) i. temperature ii. rate of oxygen consumption iii.
    [Show full text]
  • Analytic Epidemiology Analytic Studies: Observational Study
    Analytic Studies: Observational Study Designs Cohort Studies Analytic Epidemiology Prospective Cohort Studies Retrospective (historical) Cohort Studies Part 2 Case-Control Studies Nested case-control Case-cohort studies Dr. H. Stockwell Case-crossover studies Determinants of disease: Analytic Epidemiology Epidemiology: Risk factors Identifying the causes of disease A behavior, environmental exposure, or inherent human characteristic that is associated with an important health Testing hypotheses using epidemiologic related condition* studies Risk factors are associated with an increased probability of disease but may Goal is to prevent disease (deterrents) not always cause the diseases *Last, J. Dictionary of Epidemiology Analytic Studies: Cohort Studies Panel Studies Healthy subjects are defined by their Combination of cross-sectional and exposure status and followed over time to cohort determine the incidence of disease, symptoms or death Same individuals surveyed at several poiiiints in time Subjects grouped by exposure level – exposed and unexposed (f(reference group, Can measure changes in individuals comparison group) Analytic Studies: Case-Control Studies Nested case-control studies A group of individuals with a disease Case-control study conducted within a (cases) are compared with a group of cohort study individuals without the disease (controls) Advantages of both study designs Also called a retrospective study because it starts with people with disease and looks backward for ppprevious exposures which might be
    [Show full text]
  • 1 Sensitivity Analysis in Observational Research: Introducing the E-‐Value
    Sensitivity Analysis in Observational Research: Introducing the E-value Tyler J. VanderWeele, Ph.D., Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health Peng Ding, Ph.D., Department of Statistics, University of California, Berkeley This is the prepublication, author-produced version of a manuscript accepted for publication in Annals of Internal Medicine. This version does not include post-acceptance editing and formatting. The American College of Physicians, the publisher of Annals of Internal Medicine, is not responsible for the content or presentation of the author-produced accepted version of the manuscript or any version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any ancillary material related to this manuscript (e.g., correspondence, corrections, editorials, linked articles) should go to Annals.org or to the print issue in which the article appears. Those who cite this manuscript should cite the published version, as it is the official version of record: VanderWeele, T.J. and Ding, P. (2017). Sensitivity analysis in observational research: introducing the E-value. Annals of Internal Medicine, 167(4):268-274. 1 Abstract. Sensitivity analysis can be useful in assessing how robust associations are to potential unmeasured or uncontrolled confounding. In this paper we introduce a new measure that we call the “E-value,” a measure related to the evidence for causality in observational studies, when they are potentially subject to confounding. The E-value is defined as the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the treatment and the outcome to fully eXplain away a specific treatment-outcome association, conditional on the measured covariates.
    [Show full text]
  • Definition of Clinical Trials
    Clinical Trials A clinical trial is a prospective biomedical or behavioral research study of human subjects that is designed to answer specific questions about biomedical or behavioral interventions (vaccines, drugs, treatments, devices, or new ways of using known drugs, treatments, or devices). Clinical trials are used to determine whether new biomedical or behavioral interventions are safe, efficacious, and effective. Clinical trials include behavioral human subjects research involving an intervention to modify behavior (increasing the use of an intervention, willingness to pay for an intervention, etc.) Human subjects research to develop or evaluate clinical laboratory tests (e.g. imaging or molecular diagnostic tests) might be considered to be a clinical trial if the test will be used for medical decision-making for the subject or the test itself imposes more than minimal risk for subjects. Biomedical clinical trials of experimental drug, treatment, device or behavioral intervention may proceed through four phases: Phase I clinical trials test a new biomedical intervention in a small group of people (e.g., 20- 80) for the first time to evaluate safety (e.g., to determine a safe dosage range, and to identify side effects). Phase II clinical trials study the biomedical or behavioral intervention in a larger group of people (several hundred) to determine efficacy and to further evaluate its safety. Phase III studies investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand) by comparing the intervention to other standard or experimental interventions as well as to monitor adverse effects, and to collect information that will allow the intervention to be used safely.
    [Show full text]
  • Chapter 20 Design and Analysis of Experiments and Observational
    Chapter 20 Design and Analysis of Experiments and Observational Studies Point of both observational studies and designed experiments is to identify variable or set of variables, called explanatory variables, which are thought to predict outcome or response variable. Observational studies are an investigation of the association between treatment and response, where subject who decide whether or not they take a treatment. In experimental designs, experimenter decides who is given a treat- ment and who is to be a control, the experimenter alters levels of treatments when investigating how these alterations cause change in the response. 20.1 Observational Studies Exercise 20.1 (Observational Studies) 1. Observational Study versus Designed Experiment. (a) Effect of air temperature on rate of oxygen consumption (ROC) of four mice is investigated. ROC of one mouse at 0o F is 9.7 mL/sec for example. temperature (Fo) 0 10 20 30 ROC (mL/sec) 9.7 10.3 11.2 14.0 Since experimenter (not a mouse!) decides which mice are subjected to which temperature, this is (choose one) observational study / designed experiment. (b) Indiana police records from 1999–2001 on six drivers are analyzed to de- termine if there is an association between drinking and traffic accidents. One heavy drinker had 6 accidents for example. 169 170Chapter 20. Design and Analysis of Experiments and Observational Studies (lecture notes 10) drinking → heavy light 3 1 6 2 2 1 This is an observational study because (choose one) i. police decided who was going to drink and drive and who was not. ii. drivers decided who was going to drink and drive and who was not.
    [Show full text]